Prevalence of gestational choriocarcinoma in a parous population in ten years


  • Fatma Al Wahaibi Department of Obstetrics and Gynecology, Sultan Qaboos University, Muscat, Oman
  • Vaidyanathan Gowri Department of Obstetrics and Gynecology, Sultan Qaboos University, Muscat, Oman
  • Suad Al Kharusi Department of Medical Oncology, Royal hospital, Muscat, Oman
  • Thuria Al Rawahi Department of Obstetrics and Gynecology, Royal Hospital, Muscat, Oman



Choriocarcinoma, Parity, Prevalence


Background: Choriocarcinoma is a rare disease with varying incidence in different parts of the world. Asian, American Indian and Africans are quoted to be at a higher risk. There are no epidemiological data from Middle East and hence authors studied the prevalence of choriocarcinoma in Oman, a Middle East nation with a high parity.

Methods: This is a retrospective, descriptive, observational study done at tertiary care hospital; Royal Hospital from Jan 2010 to Dec 2019. Since all women are referred to a single center from all over the country, authors believe all cases are included over ten years.

Results: There were 22 patients and the prevalence were 1 in 36966 live births. The main presenting symptom was abnormal uterine bleeding and all were gestational type of choriocarcinoma. Median gravidity was 6 and median parity was 5. Almost 80 % received chemo as their risk scoring was more than 7 and one woman died.

Conclusions: The prevalence of choriocarcinoma was much similar to Europe and USA though the median gravidity and parity was high. Clinical features were comparable to the literature and management protocols were as per international recommendations.

Author Biography

Fatma Al Wahaibi, Department of Obstetrics and Gynecology, Sultan Qaboos University, Muscat, Oman

Department of OBGYN, Specialist


Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, et al. Trophoblastic disease review for diagnosis and management a joint report from the international society for the study of trophoblastic disease, european organization for the treatment of trophoblastic disease, and the gynecologic cancer inter group. Int J Gynecol Cancer. 2014;24:S109-16.

Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531-9.

Zhang W, Liu B, Wu J, Sun B. Hemoptysis as primary manifestation in three women with choriocarcinoma with pulmonary metastasis: a case series. J Med Case Repo. 2017;11(1):1-5.

Cheung AN, Zhang HJ, Xue WC, Siu MK. Pathogenesis of choriocarcinoma: clinical, genetic and stem cell perspectives. Future Oncol. 2009;5(2):217-31.

Feng F, Xiang Y. Surgical management of chemotherapy-resistant gestational trophoblastic neoplasia. Expert Rev Anticancer Ther. 2010;10(1):71-80.

Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med. 2006;51(10):773-6.

Chen MJ, Yang JH, Lin MC, Ho HN, Yang YS. An unusual gestational choriocarcinoma occurring primarily in the surface of subserous leiomyoma. BJOG. 2004;111:188e90.

Salleh S, Arthrur I. Persistent peritoneal trophoblastic implantation following salpingotomy, salpingectomy and methotrexate for ectopic pregnancy. Gynecol Surg. 2005;2:195e6.

Hassadia A, Kew FM, Tidy JA, Wells M, Hancock BW. Ectopic gestational trophoblastic disease: a case series review. J Reprod Med. 2012;57:297e300.

Soper JT, Mutch DG, Schink JC. American college of obstetricians and gynaecologists diagnosis and treatment of gestational trophoblastic disease; ACOG practice bulletein no. 53. Gynecol Oncol. 2004;93:575e85.

Berkowitz RS, Goldstein DP. Gestational Trophoblastic Disease. In: Berek J, editor. Berek and Novak's Gynecology. Philadelphia: Lippincott Williams and Wilkins; 2007:1581e603.

Stockton L, Green E, Kaur B, De Winton E. Non-gestational choriocarcinoma with widespread metastases presenting with type 1 respiratory failure in a 39-year-old female: case report and review of the literature. Case Rep Oncol. 2018;11(1):1-5.

Ngan S, Seckl MJ. Gestational trophoblastic neoplasia management: an update. Curr Opin Oncol. 2007;19:486.

Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet. 2018;143 Suppl 2:79.

Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2009;112:654.

Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. The Lancet. Oncology. 2003;4(11):670-8.

Sita-Lumsden A, Short D, Lindsay I, Sebire NJ, Adjogatse D, Seckl MJ, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009. Br J Cancer. 2012;107(11):1810-4.

McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol. 2002;20:1838.






Original Research Articles